{"id":743813,"date":"2013-03-13T08:30:00","date_gmt":"2013-03-13T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/"},"modified":"2023-03-22T00:04:40","modified_gmt":"2023-03-22T04:04:40","slug":"merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/","title":{"rendered":"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease"},"content":{"rendered":"<p class=\"bwalignc\">       Collaboration to Support Patient Selection for the Clinical        Development of MK-8931, Merck\u2019s Lead Investigational Medicine for        Alzheimer\u2019s Disease     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and<br \/>\n      license agreement to develop a companion diagnostic device that will be<br \/>\n      evaluated to help screen patients for recruitment into Merck&#8217;s clinical<br \/>\n      development program for MK-8931, a novel oral beta amyloid precursor<br \/>\n      protein site cleaving enzyme (BACE) inhibitor and Merck&#8217;s lead<br \/>\n      investigational candidate for Alzheimer&#8217;s disease (AD). Financial terms<br \/>\n      were not disclosed.\n    <\/p>\n<p>\n      \u201cEvaluation of biomarkers that may provide an indicator of disease onset<br \/>\n      and enable earlier diagnosis is an important goal toward facilitating<br \/>\n      early intervention and potentially improving the treatment of<br \/>\n      Alzheimer\u2019s disease,\u201d said Darryle D. Schoepp, Ph.D., senior vice<br \/>\n      president, head of Neuroscience and Ophthalmology at Merck Research<br \/>\n      Laboratories. \u201cWe look forward to working with Luminex to advance our<br \/>\n      ongoing clinical development program for MK-8931.\u201d\n    <\/p>\n<p>\n      Luminex will be responsible for development, regulatory submission and<br \/>\n      commercialization of the candidate companion diagnostic device, which<br \/>\n      will employ Luminex\u2019s xMAP\u00ae Technology to measure concentrations of two<br \/>\n      candidate biomarkers (A\u03b242 and t-tau) in cerebrospinal fluid (CSF)<br \/>\n      samples from patients with mild cognitive impairment (MCI). The<br \/>\n      candidate device will be evaluated as a means to identify subjects with<br \/>\n      MCI who have a higher risk of developing AD to support patient selection<br \/>\n      for Merck\u2019s therapeutic BACE inhibitor clinical program.\n    <\/p>\n<p>\n      \u201cThis collaboration has the potential to deliver a novel companion<br \/>\n      diagnostic to identify patients at increased risk of developing<br \/>\n      Alzheimer\u2019s disease,\u201d added Patrick J. Balthrop, president and CEO of<br \/>\n      Luminex. \u201cWe are pleased to leverage our technologies and development<br \/>\n      capabilities and look forward to expanding our activity into the<br \/>\n      companion diagnostic segment of personalized medicine.\u201d\n    <\/p>\n<p>\n      The accumulation of beta amyloid in the brain is a key pathological<br \/>\n      characteristic related to AD. Recent clinical evidence supports the<br \/>\n      hypothesis that the measurement of the investigational biomarkers A\u03b242<br \/>\n      and t-tau in CSF may be useful in identifying patients at greater risk<br \/>\n      of developing AD. Currently, AD is diagnosed by clinical examination<br \/>\n      (i.e., medical history; physical, neurological, psychiatric and<br \/>\n      neuropsychological exams; and Magnetic Resonance Imaging [MRI] or<br \/>\n      Computed Tomography [CT] scan). An AD diagnosis can only be confirmed by<br \/>\n      histopathological identification of core features, including beta<br \/>\n      amyloid deposits and plaques, in post-mortem brain samples.\n    <\/p>\n<p>\n      <b>About Alzheimer&#8217;s Disease and Amyloid Hypothesis<\/b>\n    <\/p>\n<p>\n      Alzheimer\u2019s disease (AD) is a devastating, irreversible and ultimately<br \/>\n      fatal disease that progressively destroys neurons in the brain, leading<br \/>\n      to a deterioration of cognitive function. The symptoms include loss of<br \/>\n      memory that progresses into behavioral changes, alterations in thinking<br \/>\n      and reasoning skills that interfere with daily activities, and dementia.<br \/>\n      AD is the most common cause of dementia, accounting for approximately<br \/>\n      50-75 percent of the estimated 35 million dementia cases globally.<sup>1,2<\/sup><br \/>\n      About 5.4 million people in the United States are currently living with<br \/>\n      AD.<sup>3<\/sup> There are currently no disease-modifying treatments<br \/>\n      available for AD, and treatment options are limited to providing<br \/>\n      symptomatic improvements with only modest and short-term effects.\n    <\/p>\n<p>\n      While the exact cause of AD remains unknown, the current prevailing<br \/>\n      hypothesis asserts that AD occurs due to the accumulation of beta<br \/>\n      amyloid proteins in the brain. Beta amyloid precursor protein site<br \/>\n      cleaving enzyme (BACE) is believed to be a key enzyme in the production<br \/>\n      of beta amyloid peptide, which contributes to the formation of plaques<br \/>\n      in the brain. Evidence suggests that inhibiting BACE decreases the<br \/>\n      production of beta amyloid and may therefore reduce amyloid plaque<br \/>\n      formation and modify disease progression.\n    <\/p>\n<p>\n      <b>About Merck\u2019s BACE Inhibitor Development Program and MK-8931<\/b>\n    <\/p>\n<p>\n      Merck is advancing several innovative programs in Alzheimer&#8217;s disease,<br \/>\n      including candidates designed to modify disease progression as well as<br \/>\n      improve symptom control. Merck&#8217;s lead candidate in disease modification<br \/>\n      is MK-8931, an investigational oral BACE inhibitor.\n    <\/p>\n<p>\n      Results of Phase I clinical studies demonstrated that MK-8931 can reduce<br \/>\n      levels of beta amyloid in cerebral spinal fluid (CSF) by greater than 90<br \/>\n      percent in healthy volunteers and people with AD without dose-limiting<br \/>\n      side effects. Based on these results, Merck is conducting a global,<br \/>\n      multi-center Phase II\/III clinical trial, EPOCH, to evaluate the safety<br \/>\n      and efficacy of MK-8931 versus placebo in patients with mild-to-moderate<br \/>\n      AD and has plans to initiate a trial in prodromal subjects. Information<br \/>\n      is also available at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=50589439&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=5a638ec5c6ee5c5b66265d0dc189dfb6\">www.clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      In December 2012, Merck and GE Healthcare announced a clinical study<br \/>\n      collaboration, license and supply agreement for use of [<sup>18<\/sup>F]Flutemetamol,<br \/>\n      an investigational positron emission tomography (PET) imaging agent, to<br \/>\n      support development of MK-8931.\n    <\/p>\n<p>\n      <b>About Luminex Corporation<\/b>\n    <\/p>\n<p>\n      Luminex is committed to applying its passion for innovation toward<br \/>\n      creating breakthrough solutions to improve health and advance science.<br \/>\n      The company is transforming global healthcare and life-science research<br \/>\n      through the development, manufacturing and marketing of proprietary<br \/>\n      instruments and assays utilizing xMAP\u00ae open-architecture multi-analyte<br \/>\n      platform, MultiCode\u00ae real-time polymerase chain reaction (PCR), and<br \/>\n      multiplex PCR-based technologies, that deliver cost-effective rapid<br \/>\n      results to clinicians and researchers. Luminex&#8217;s technology is<br \/>\n      commercially available worldwide and in use in leading clinical<br \/>\n      laboratories, as well as major pharmaceutical, diagnostic, biotechnology<br \/>\n      and life-science companies. Luminex is meeting the needs of customers in<br \/>\n      markets as diverse as clinical diagnostics, pharmaceutical drug<br \/>\n      discovery, biomedical research including genomic and proteomic research,<br \/>\n      personalized medicine, biodefense research and food safety. For further<br \/>\n      information on Luminex Corporation and the latest advances in<br \/>\n      multiplexing using award winning technology, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.luminexcorp.com&amp;esheet=50589439&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.luminexcorp.com&amp;index=2&amp;md5=0d5f9df19c06de8a49bc3ee0b1f0a047\">http:\/\/www.luminexcorp.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50589439&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=9cf747d1bed8fd6017c8a6344f0307de\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Luminex Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      Statements made in this release that express Luminex\u2019s or management\u2019s<br \/>\n      intentions, plans, beliefs, expectations or predictions of future events<br \/>\n      are forward-looking statements. Forward-looking statements in this<br \/>\n      release include statements regarding our collaboration with Merck to<br \/>\n      develop, manufacture and distribute a companion diagnostic product for<br \/>\n      detection of Alzheimer\u2019s disease. The words &#8220;believe,&#8221; &#8220;expect,&#8221;<br \/>\n      &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should&#8221; and<br \/>\n      similar expressions are intended to further identify such<br \/>\n      forward-looking statements for purposes of the Private Securities<br \/>\n      Litigation Reform Act of 1995. It is important to note that the<br \/>\n      Company\u2019s actual results or performance could differ materially from<br \/>\n      those anticipated or projected in such forward-looking statements.<br \/>\n      Factors that could cause Luminex\u2019s actual results or performance to<br \/>\n      differ materially include risks and uncertainties relating to, among<br \/>\n      others, market demand and acceptance of this product and Luminex<br \/>\n      technology generally, our ability to ability to complete product<br \/>\n      development, scale up manufacturing, secure required regulatory<br \/>\n      clearance, and distribute the product, as well as the risks discussed<br \/>\n      under the heading &#8220;Risk Factors&#8221; in Luminex\u2019s Reports on Forms 10-K and<br \/>\n      10-Q, as filed with the Securities and Exchange Commission. The<br \/>\n      forward-looking statements contained herein represent the judgment of<br \/>\n      Luminex as of the date of this press release, and Luminex expressly<br \/>\n      disclaims any intent, obligation or undertaking to release publicly any<br \/>\n      updates or revisions to any forward-looking statements to reflect any<br \/>\n      change in Luminex\u2019s expectations with regard thereto or any change in<br \/>\n      events, conditions or circumstances on which any such statements are<br \/>\n      based.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50589439&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=024d944e241071927d25295bfe045e8e\">www.sec.gov<\/a>).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n          __________________________\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\">\n<p class=\"bwcellpmargin\">\n            <sup>1<\/sup> Alzheimer\u2019s Disease International. Types of Dementia:<br \/>\n            Alzheimer\u2019s Disease. Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alz.co.uk%2Finfo%2Falzheimers-disease&amp;esheet=50589439&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.alz.co.uk%2Finfo%2Falzheimers-disease&amp;index=5&amp;md5=ceaeb8e8405766a663d90221f13b01e9\">http:\/\/www.alz.co.uk\/info\/alzheimers-disease<\/a>.\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <sup>2<\/sup> Alzheimer\u2019s Disease International. Dementia<br \/>\n            Statistics. Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alz.co.uk%2Fresearch%2Fstatistics&amp;esheet=50589439&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.alz.co.uk%2Fresearch%2Fstatistics&amp;index=6&amp;md5=4735c8beb7de2461bc0350ad2ea32503\">http:\/\/www.alz.co.uk\/research\/statistics<\/a>.\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <sup>3<\/sup> Alzheimer\u2019s Association. Alzheimer\u2019s Fact and<br \/>\n            Figures. Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alz.org%2Falzheimers_disease_facts_and_figures.asp&amp;esheet=50589439&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.alz.org%2Falzheimers_disease_facts_and_figures.asp&amp;index=7&amp;md5=7210a7b9207cf0dee4a03eaee96935b0\">http:\/\/www.alz.org\/alzheimers_disease_facts_and_figures.asp<\/a>.\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20130313005378\/en\/\">http:\/\/www.businesswire.com\/multimedia\/home\/20130313005378\/en\/<\/a><\/span><\/p>\n<p>       Media Contacts:<br \/>Merck<br \/>Caroline Lappetito,        267-305-7639<br \/>or<br \/>Luminex<br \/>Mimi Torrington, 512-219-8020<br \/><a href=\"mailto:mtorrington@luminexcorp.com\">mtorrington@luminexcorp.com<\/a><br \/>or<br \/>Investor        Contacts:<br \/>Merck<br \/>Carol Ferguson, 908-423-4465<br \/>or<br \/>Luminex<br \/>Matt        Scalo, 512-336-3587<br \/><a href=\"mailto:mscalo@luminexcorp.com\">mscalo@luminexcorp.com<\/a>     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck\u2019s Lead Investigational Medicine for Alzheimer\u2019s Disease Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck&#8217;s clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck&#8217;s lead investigational candidate for Alzheimer&#8217;s disease (AD). Financial terms were not disclosed. \u201cEvaluation of biomarkers that may provide an indicator of disease onset and enable earlier diagnosis is an important goal toward facilitating early intervention and potentially improving the treatment of Alzheimer\u2019s disease,\u201d said Darryle D. Schoepp, Ph.D., senior vice president, head of Neuroscience and Ophthalmology at Merck Research<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,56],"class_list":["post-743813","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck\u2019s Lead Investigational Medicine for Alzheimer\u2019s Disease Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck&#039;s clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck&#039;s lead investigational candidate for Alzheimer&#039;s disease (AD). Financial terms were not disclosed. \u201cEvaluation of biomarkers that may provide an indicator of disease onset and enable earlier diagnosis is an important goal toward facilitating early intervention and potentially improving the treatment of Alzheimer\u2019s disease,\u201d said Darryle D. Schoepp, Ph.D., senior vice president, head of Neuroscience and Ophthalmology at Merck Research\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:40+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/\",\"name\":\"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2013-03-13T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease - Merck.com","og_description":"Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck\u2019s Lead Investigational Medicine for Alzheimer\u2019s Disease Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD). Financial terms were not disclosed. \u201cEvaluation of biomarkers that may provide an indicator of disease onset and enable earlier diagnosis is an important goal toward facilitating early intervention and potentially improving the treatment of Alzheimer\u2019s disease,\u201d said Darryle D. Schoepp, Ph.D., senior vice president, head of Neuroscience and Ophthalmology at Merck Research","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:40+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/","name":"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2013-03-13T08:30:00+00:00","dateModified":"2023-03-22T04:04:40+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20130313005378r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-luminex-corporation-enter-agreement-to-develop-companion-diagnostic-to-support-investigational-bace-inhibitor-clinical-development-program-for-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"cc513aea-318c-4b4e-8fd1-f736b53bff5b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Luminex-Corporation-Enter-Agreement-to-Develop-Companion-Diagnostic-to-Support-Investigational-BACE-inhibitor-Clinical-Deve-DX2J8.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743813\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743813"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}